Elettra-Sincrotrone Trieste S.C.p.A. website uses session cookies which are required for users to navigate appropriately and safely. Session cookies created by the Elettra-Sincrotrone Trieste S.C.p.A. website navigation do not affect users' privacy during their browsing experience on our website, as they do not entail processing their personal identification data. Session cookies are not permanently stored and indeed are cancelled when the connection to the Elettra-Sincrotrone Trieste S.C.p.A. website is terminated.
More info


Avoiding the Raft: Losartan´s Affinity to Fluid Bilayers

Figure 1. A possible scenario for losartan plasma membrane interactions is presented in panel E. Due to the denser lipid packing in the cholesterol rich rafts, losartan is likely to be excluded from this area, and preferentially found in the more fluid plasma membrane regions. Here losartan can accumulate and finally reach the AT1 receptor site.

We examined losartan’s action in different biomimetic membrane models. Losartan is an angiotensin II receptor antagonist mainly used for the regulation of high blood pressure, and structural details on its incorporation into the biomembrane interface have been studied by small angle X-ray scattering. We found that losartan tends to avoid cholesterol-rich membrane domains.
Losartan is an angiotensin II receptor antagonist mainly used for the regulation of high blood pressure. Since it was anticipated that losartan reaches the receptor site via membrane diffusion, the impact of losartan on model membranes has been investigated by small angle X-ray scattering. For this purpose 2–20 mol% losartan was incorporated into dimyristoyl-phosphatidylcholine (DMPC) and palmitoyl-oleoyl-phosphatidylcholine (POPC) bilayers and into their binary mixtures with cholesterol in the concentration range of 0 to 40 mol%. Effects of losartan on single component bilayers are alike. Partitioning of losartan into the membranes confers a negative charge to the lipid bilayers that causes the formation of unilamellar vesicles and a reduction of the bilayer thickness by 3-4%. Analysis of the structural data resulted in an estimate for the partial area of losartan, ALos ~ 40 Å2. In the presence of cholesterol, differences between the effects of losartan on POPC and DMPC are striking. Membrane condensation by cholesterol is retarded by losartan in POPC. This contrasts with DMPC, where an increase of the cholesterol content shifts the partitioning equilibrium of losartan towards the aqueous phase, such that losartan gets depleted from the bilayers from 20 mol% cholesterol onwards.

This indicates (i) a chain-saturation dependent competition of losartan with lipid-cholesterol interactions, and (ii) the insolubility of losartan in the liquid ordered phase of PCs. Consequently, losartan’s action is more likely to take place in fluid plasma membrane patches rather than in domains rich in cholesterol and saturated lipid species such as in membrane rafts.


Figure 2.  Structural results overview: Schematic illustration of POPC (A) and DMPC (B) bilayer structure alterations induced by losartan. In both cases the up-take of losartan leads to membrane unbinding (losartan concentration xLos = 0.2). At very high cholesterol concentrations losartan still finds shelter in the POPC-Chol bilayer (C), whereas it gets expelled from DMPC–Chol membranes (D) (xChol = 0.4).

Retrieve article

Losartan's affinity to fluid bilayers modulates lipid-cholesterol interactions;
A. Hodzic, P. Zoumpoulakis, G. Pabst, T. Mavromoustakos, M. Rappolt;
Phys. Chem. Chem. Phys. 14, 4780 (2012);

Last Updated on Tuesday, 14 May 2019 17:05